The Effect of Dantonic Pill onβ-Catenin Expression in a Rat Model of Streptozotocin-Induced Early Stage of Diabetic Nephropathy | Zendy

Zhou Shuhong | Zendy; Hongjun Lv | Zendy; Bo Cui | Zendy; Xu Li | Zendy; Bingyin Shi | Zendy

Open Access

The Effect of Dantonic Pill onβ-Catenin Expression in a Rat Model of Streptozotocin-Induced Early Stage of Diabetic Nephropathy

Author(s) -

Zhou Shuhong,

Hongjun Lv,

Bo Cui,

Xu Li,

Bingyin Shi

Publication year - 2013

Publication title -

journal of diabetes research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.034

H-Index - 50

eISSN - 2314-6753

pISSN - 2314-6745

DOI - 10.1155/2013/848679

Subject(s) - diabetic nephropathy , irbesartan , streptozotocin , medicine , renal cortex , endocrinology , albuminuria , glomerular basement membrane , diabetes mellitus , downregulation and upregulation , renal function , kidney , urology , proteinuria , chemistry , biochemistry , blood pressure , gene

Diabetic nephropathy (DN) is one of the most common causes of end-stage renal failure. This study was performed to determine the effect of Dantonic Pill (DP) treatment on β -catenin expression in a rat model of streptozotocin- (STZ-) induced early-stage DN, with irbesartan treatment as a positive control. Including an analysis of the general metabolic index and renal function, immunohistochemical staining and reverse transcription real-time PCR for β -catenin were performed in the renal cortex of the rat models every 4 weeks. After the treatments of DP and irbesartan, the albuminuria level, kidney weight/body weight, and thickness of the glomerular basement membrane were decreased, but the expression of β -catenin was not downregulated in the renal cortex. The effective drug target of DP to ameliorate albuminuria and renal hypertrophy should not inhibit the upregulated expression of β -catenin in rats with STZ-induced early-stage diabetic damage.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research